Regenerative medicine in Korea, explained from the evidence
Evidence levelBy modalityEvidence register
| Modality | Evidence level | Regulatory status | What to ask |
|---|---|---|---|
| Autologous cells (MSC, SVF, ADSC) | Systematic review of cell-assisted lipotransfer, where cells are added to a fat graft rather than injected as a treatment in themselves. Graft-retention rates in the underlying literature range from roughly 25% to 80%. Processing methods are not standardised between clinics. What it is | US FDA approval for aesthetic indicationsNone for cosmetic use | Is this conducted as treatment or as clinical research, and under what authorisation? |
| Exosomes / extracellular vesicles | Small controlled trials and systematic reviews of extracellular vesicles and conditioned media; formulation and procedure differences limit generalisation. No exosome product holds US FDA approval for any indication. Isolation and characterisation methods differ between suppliers, so "exosome" on two labels need not mean the same material. What it is | US FDA approval for aesthetic indicationsNone: no exosome product is approved for any indication | What exactly is being injected, and where did it come from? |
| Platelet-rich plasma (PRP) | Multiple systematic reviews and meta-analyses of randomised controlled trials, chiefly in androgenetic alopecia. A 2023 systematic review graded the certainty of benefit as low, citing inconsistency and risk of bias. Preparation protocols vary between studies. What it is | What is the strongest published evidence for this, in my indication? | |
| PDRN / polynucleotides (PN) | A systematic review of nine studies in aesthetic use, plus a substantial pharmacology literature on PDRN in wound healing. The included aesthetic studies were of low to moderate quality, with 219 patients in total and no consensus on optimal use. What it is | What is the realistic range of outcomes, including no visible change? |
Korea regulates interventions within its statutory advanced regenerative medicine pathway through designated institutions and plan review. Specified minimally manipulated cell and tissue procedures are excluded from that pathway. Under one word, “regenerative”, sits a whole spectrum of products: living cells, platelet concentrates, cell-free vesicles, purified DNA fragments, each with its own evidence base. Parts of that spectrum are genuinely well studied: PRP for pattern hair loss has multiple meta-analyses of randomised trials, whose reviewers grade the certainty as low[3], while exosome products, for all their mechanistic promise, hold no United States FDA approval yet for any indication[1].
Questions to ask a clinic in Seoul
If you are considering a regenerative procedure in Seoul, use the eight-question checklist to ask about the product, evidence, risks and follow-up before agreeing.
What the product contains
Ask what is physically in the syringe. That single question sorts the field better than any brand name, because it predicts both what a regulator will call the product and what kind of study anyone has managed to run on it.
Living nucleated cells
- Autologous MSCs
- Stromal vascular fraction
- Adipose-derived cells
Anucleate fragments in plasma
- Platelet-rich plasma (PRP)
Cell-derived preparations
- Conditioned cell-culture medium
- Exosomes and other extracellular vesicles
No cellular material
- PDRN
- Polynucleotides (PN)
At one end sit preparations containing living nucleated cells: autologous mesenchymal stromal cells, stromal vascular fraction, adipose-derived cells. These are the products that the phrase “stem cell treatment” literally describes, and their regulatory status depends on processing and intended use. At the other end sit polynucleotides and PDRN: purified DNA fragments, in the case of PDRN derived from salmon sperm, containing no cellular material whatsoever[4].
In between are two categories that cause most of the confusion. Platelet-rich plasma is your own blood, spun down so that platelets are concentrated in a small volume of plasma: anucleate cell fragments, not stem cells. And exosomes are small vesicles released by cells, which are not living cells. The composition and purity of a preparation must be checked separately. That last category is the one where the vocabulary has run furthest ahead of the science; the International Society for Extracellular Vesicles has had to publish successive editions of minimum reporting standards partly because laboratories could not agree on what they were even measuring[5]. The difference between stem cells and exosomes is worth understanding before reading any clinic page on either.
Clinical evidence and its limits
Regenerative products have been studied in cell cultures, case series, controlled trials and systematic reviews. Exosome-containing preparations have small controlled studies and systematic reviews, but variations in formulation, combined procedures and short follow-up limit the conclusions[7,8].
PRP for pattern hair loss has multiple meta-analyses of randomised trials. Cruciani and colleagues’ 2023 review included 18 androgenetic-alopecia trials with 713 participants and nine alopecia-areata trials with 404 participants; its certainty assessment found that evidence of benefit was limited and mostly low quality[3]. That is what a mature evidence base looks like in this field. Modalities with less research behind them are not better; they are just less examined. How to read evidence levels in regenerative medicine.
The regulatory picture, in two jurisdictions
US and Korean regulators determine status within their own jurisdictions. The United States FDA has published a standing consumer alert about regenerative medicine products including stem cells and exosomes, which is the document to read before weighing any claim about American approval status. Korea regulates advanced regenerative medicine through its own statute, which requires institutional designation and plan review for interventions within its defined scope and excludes specified minimally manipulated cell and tissue procedures.
Neither fact tells you whether a particular clinic is operating properly. That is the part readers most often get wrong: a statute existing is not a clinic being licensed under it, and a paper being published is not a product being approved. Both the Korean framework and the FDA-approval question require separate records.
Medical tourism raises the stakes
A reader considering travelling for a regenerative procedure is taking on a risk profile that a local patient does not. A critical review of international stem cell tourism found that clinics offering these therapies are concentrated in jurisdictions with lighter oversight, that reported complications include infection, immune rejection and tumour formation, and that follow-up care after returning home is frequently nobody’s responsibility[6]. If you are reading this from outside Korea, the safety page and the list of questions to ask a clinic cover follow-up arrangements and the documents to obtain before travel. Directions and booking information for visitors from abroad are on the international-patient page at Delight Dermatology.
References
- Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. J Drugs Dermatol. 2025;24(1):12-18. doi:10.36849/JDD.8872 · PMID:39761139
- Shah M, Dukharan V, Broughton L, et al. Exosomes for Aesthetic Dermatology: A Comprehensive Literature Review and Update. J Cosmet Dermatol. 2025;24(1):e16766. doi:10.1111/jocd.16766 · PMID:39764639
- Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. Blood Transfus. 2023;21(1):24-36. doi:10.2450/2021.0216-21 · PMID:34967722
- Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. J Cosmet Dermatol. 2025;24(2):e16721. doi:10.1111/jocd.16721 · PMID:39645667
- Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. doi:10.1002/jev2.12404 · PMID:38326288
- Lyons S, Salgaonkar S, Flaherty GT. International stem cell tourism: a critical literature review and evidence-based recommendations. Int Health. 2022;14(2):132-141. doi:10.1093/inthealth/ihab050 · PMID:34415026
- Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. doi:10.1111/jocd.15872 · PMID:37377400
- Jafarzadeh A, Hoseini SS, Behrangi E, Roohaninasab M, Goodarzi A. Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media. Stem Cell Res Ther. 2025;16(1):513. doi:10.1186/s13287-025-04592-z · PMID:41013717
Written by the Stem Cell Seoul editorial team and medically reviewed by a Korean board-certified dermatologist. Last reviewed 2026-08-30. Editorially updated 2026-10-18.